Barclays PLC Neurocrine Biosciences Inc Put Options Transaction History

Barclays PLC

12 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $8.61 Million - $9.85 Million	96,300 Added 770.4%	108,800 $10.6 Million
Q1 2020 May 13, 2020	BUY	$75.11 - $113.76 $270,396 - $409,536	3,600 Added 40.45%	12,500 $1.08 Million
Q4 2019 Feb 10, 2020	SELL	$86.8 - $118.57 $2.75 Million - $3.76 Million	-31,700 Reduced 78.08%	8,900 $957,000
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $176,022 - $213,150	-2,100 Reduced 4.92%	40,600 $3.66 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $837,983 - $1.06 Million	-11,600 Reduced 21.36%	42,700 $3.61 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $651,514 - $860,382	9,400 Added 20.94%	54,300 $4.78 Million
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $2.35 Million - $4.28 Million	-34,400 Reduced 43.38%	44,900 $3.21 Million
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $3.3 Million - $4.2 Million	-33,400 Reduced 29.64%	79,300 $9.75 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $2.47 Million - $3.48 Million	32,800 Added 41.05%	112,700 $11.1 Million
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $3.92 Million - $4.78 Million	-51,700 Reduced 39.29%	79,900 $6.63 Million
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $1.15 Million - $1.53 Million	-19,700 Reduced 13.02%	131,600 $10.2 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $7.26 Million - $9.27 Million	151,300	151,300 $9.27 Million

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.